[Cloning and expression of androgen response elements of prostate specific antigen promoter].
OBJECTIVE
To provide a possible targeted gene therapy scheme for prostate cancer, and explore the expression efficiency and tissue-specific expression of prostate specific antigen (PSA) promoter.


METHODS
Three plasmids with egfp, pa-EGFP(including ARI, ARII), pba-EGFP (including ARI, ARII, ARIII) and pdeltaba-EGFP (including ARI, ARII and mutated ARIII) were designed, and the expression status was observed by transfecting into HepG2, SMMC-7721, Hela and PC-3.


RESULTS
In prostate cancer cell PC-3, pba-EGFP expressed more GFP than pa-EGFP and pdeltaba-EGFP, which showed that ARIII could notably increase the transcription efficiency of PSA promoter. Further, there was no GFP expression in HepG2, SMMC-7721 and Hela transfected with pa-EGFP, p deltaba-EGFP and pba-EGFP.


CONCLUSIONS
An expression vector based on elements of the PSA gene regulatory sequences has been developed and shown to be tightly regulated in a panel of cells from tissues of various origins. With the tissue-specific functional protein, it should provide a solid platform for clinical studies.
Hu
Yu
Y
Department of Andrology, Nanjing General Hospital of Nanjing Command, PLA, Nanjing, Jiangsu 210002, China.
Shang
Xue-jun
XJ
Ge
Jing-ping
JP
Sun
Yi
Y
Huang
Yu-feng
YF
D000728:Androgens / Q000378:metabolism; D045744:Cell Line, Tumor; D003001:Cloning, Molecular; D006801:Humans; D008297:Male; D011401:Promoter Regions, Genetic; D011467:Prostate / Q000378:metabolism; D017430:Prostate-Specific Antigen / Q000096:biosynthesis / Q000235:genetics*; D020218:Response Elements; D014162:Transfection
D000728:Androgens; D017430:Prostate-Specific Antigen